Research graph
References from Hereditary cancer syndromes as a model for precision oncology: the paradigms of HRD and MSI. Local targets link to admitted publications; unresolved targets remain external evidence.
Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different?
10.14694/edbook_am.2015.35.114 · 2015 · External reference
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
10.1016/j.molonc.2011.07.001 · 2011 · External reference
Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
10.3389/fonc.2024.1405361 · 2024 · External reference
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
10.1056/nejmoa1105535 · 2012 · External reference
Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial
10.1200/jco.22.01549 · 2023 · External reference
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s1470-2045(17)30469-2 · 2017 · External reference
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s1470-2045(21)00531-3 · 2021 · External reference
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
10.1016/j.annonc.2024.08.2241 · 2024 · External reference
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
10.1056/nejmoa1611310 · 2016 · External reference
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
10.1016/s1470-2045(22)00122-x · 2022 · External reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · 2017 · External reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · 2018 · External reference
Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
10.1056/nejmoa2105215 · 2021 · External reference
Overall survival results from the POLO trial: a phase III study of active maintenance Olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer
10.1200/jco.21.01604 · 2022 · External reference
Olaparib for metastatic castration-resistant prostate cancer
10.1056/nejmoa1911440 · 2020 · External reference
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
10.1038/s43018-022-00439-1 · 2022 · External reference
PARP inhibitors in pancreatic cancer with homologous recombination repair gene mutations: a single-institution experience
10.3390/cancers16203447 · 2024 · External reference
Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review
10.1038/s44276-025-00122-9 · 2025 · External reference
Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial
10.1200/jco.23.00339 · 2024 · External reference
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
10.1016/s1470-2045(21)00757-9 · 2022 · External reference
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian precision tumor-agnostic phase II study
10.1016/j.esmoop.2023.102041 · 2023 · External reference
TBCRC 048 (olaparib expanded) expansion cohorts: phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s)mutations in BRCA1 or BRCA2. Abstract 1021, ASCO
2024 · External reference
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations
10.1038/s41698-024-00634-6 · 2024 · External reference
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review
10.1016/j.ygyno.2021.05.018 · 2021 · External reference
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
10.1056/nejmoa1911361 · 2019 · External reference
10.1016/j.annonc.2024.08.2272
10.1016/j.annonc.2024.08.2272 · 2024 · External reference
PARP inhibitors in prostate cancer—the preclinical rationale and current clinical development
10.3390/genes10080565 · 2019 · External reference
PARP inhibitors: enhancing efficacy through rational combinations
10.1038/s41416-023-02326-7 · 2023 · External reference
Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
10.1200/jco.22.01649 · 2023 · External reference
Abiraterone and Olaparib for metastatic castration-resistant prostate cancer
10.1056/evidoa2200043 · 2022 · External reference
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
10.1016/s0140-6736(23)01055-3 · 2023 · External reference
Phase 3 AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes
2025 · External reference
The interplay between PARP inhibitors and immunotherapy in ovarian cancer: the rationale behind a new combination therapy
10.3390/ijms23073871 · 2022 · External reference
Combining PARP inhibition and immunotherapy in BRCA-associated cancers
10.1007/978-3-031-30065-3_12 · 2023 · External reference
PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD/E axis in ovarian cancer
10.1136/jitc-2024-009032 · 2024 · External reference
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
10.1001/jamaoncol.2019.1029 · 2019 · External reference
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
10.1016/s1470-2045(20)30324-7 · 2020 · External reference
Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-naïve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study
10.1158/1078-0432.ccr-23-2249 · 2024 · External reference
Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial
10.1001/jamaoncol.2022.5228 · 2023 · External reference
Unresolved reference
2025 · External reference
Abstract CT145: olaparib ± atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
10.1158/1538-7445.am2023-ct145 · 2023 · External reference
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
10.1038/s43018-020-00148-7 · 2021 · External reference
Prevalence of homologous recombination deficiency in first-line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer
10.3390/cancers15123095 · 2023 · External reference
Targeting DNA repair to drive immune responses: it's time to reconsider the strategy for clinical translation
10.1158/1078-0432.ccr-19-3841 · 2020 · External reference
Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without Olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial
10.1200/jco.23.02132 · 2024 · External reference
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
2019 · External reference
Targeting DNA repair in cancer: beyond PARP inhibitors
10.1158/2159-8290.cd-16-0860 · 2017 · External reference
STING directly interacts with PAR to promote apoptosis upon acute ionizing radiation-mediated DNA damage
10.1038/s41418-025-01457-z · 2025 · External reference
Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors
10.1016/j.critrevonc.2023.104233 · 2024 · External reference
Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
10.20892/j.issn.2095-3941.2023.0260 · 2024 · External reference
EFFORT: efficacy of adavosertib in parp resistance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer
10.1200/jco.2021.39.15_suppl.5505 · 2021 · External reference
ADAGIO: a phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma
2024 · External reference
Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues
10.1158/1535-7163.mct-23-0681 · 2024 · External reference
Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with cytotoxic chemotherapy or novel anti-cancer agents (AToM Study)
2017 · External reference
Microsatellite instability in colorectal cancer
10.1053/j.gastro.2009.12.064 · 2010 · External reference
Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer
1995 · External reference
Comprehensive molecular characterization of human colon and rectal cancer
10.1038/nature11252 · 2012 · External reference
PD-1 blockade in tumors with mismatch-repair deficiency
10.1056/nejmoa1500596 · 2015 · External reference
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · 2017 · External reference
Unresolved reference
2017 · External reference
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
10.1056/nejmoa2017699 · 2020 · External reference
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
10.1016/j.annonc.2024.11.012 · 2025 · External reference
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
10.1200/jco.2017.76.9901 · 2018 · External reference
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
10.1016/j.annonc.2022.06.008 · 2022 · External reference
NCCN clinical practice guidelines in oncology: uterine neoplasms. Version 3.2025
2025 · External reference
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study
10.1200/jco.19.02105 · 2020 · External reference
10.1136/jitc-2021-003777
10.1136/jitc-2021-003777 · 2022 · External reference
Dostarlimab for primary advanced or recurrent endometrial cancer
10.1056/nejmoa2216334 · 2023 · External reference
Landscape of microsatellite instability across 39 cancer types
2017 · External reference
Microsatellite instability is highly prevalent in older patients with colorectal cancer
10.3389/fsurg.2024.1288061 · 2024 · External reference
Microsatellite instability in colorectal cancer
2018 · External reference
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer
10.1002/bjs.10663 · 2018 · External reference
Genomic profiling of small-bowel adenocarcinoma
10.1001/jamaoncol.2017.1051 · 2017 · External reference
A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
10.1038/s41598-022-23319-1 · 2022 · External reference
Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors
10.1111/cas.14798 · 2021 · External reference
Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations
10.1158/1078-0432.ccr-17-3099 · 2018 · External reference
Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: a systematic review and meta-analysis
10.1016/j.ygyno.2022.12.008 · 2023 · External reference
Integrated genomic characterization of endometrial carcinoma
10.1038/nature12113 · 2013 · External reference
Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer
10.1002/cncr.30496 · 2017 · External reference
New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis
10.1093/hmg/ddu058 · 2014 · External reference
Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types
10.1001/jamaoncol.2019.2963 · 2019 · External reference
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation
10.1038/s41392-024-01939-5 · 2024 · External reference
166 POLE/POLD1 mutations as predictive biomarkers for immunotherapy response: insights from a pan-cancer real-world dataset
2024 · External reference
Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers
2022 · External reference
Tumor mutational burden and response rate to PD-1 inhibition
10.1056/nejmc1713444 · 2017 · External reference
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
10.1136/jitc-2021-003091 · 2022 · External reference
Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer
10.1158/1078-0432.ccr-23-3403 · 2024 · External reference
A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/dMMR gastrointestinal tumors
10.1158/1078-0432.ccr-21-0401 · 2021 · External reference
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
10.1056/nejmoa1801946 · 2018 · External reference
MBD4 loss results in global reactivation of promoters and retroelements with low methylated CpG density
10.1186/s13046-023-02882-z · 2023 · External reference
MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes
10.1038/s41431-023-01418-5 · 2023 · External reference
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients
10.1016/j.ejca.2022.06.033 · 2022 · External reference
MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
10.1182/blood-2018-05-852566 · 2018 · External reference
Tackling of immunorefractory tumors by targeting alternative immune checkpoints
10.3390/cancers15102774 · 2023 · External reference
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
10.1186/s12943-019-1091-2 · 2019 · External reference
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
10.1056/nejmoa2109970 · 2022 · External reference
Unresolved reference
2022 · External reference
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma
10.1200/jco.2023.41.16_suppl.tps9602 · 2023 · External reference
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
10.1016/s1470-2045(22)00226-1 · 2022 · External reference
SKYSCRAPER-01: a phase III, randomized trial of tiragolumab (tira) plus atezolizumab (atezo) versus placebo (pbo) plus atezolizumab in patients with previously untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC
2025 · External reference
IMbrave152/SKYSCRAPER-14: a phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
10.1080/14796694.2024.2355863 · 2024 · External reference
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
10.1186/s12885-023-11534-6 · 2023 · External reference
Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors
10.1158/1078-0432.ccr-20-4746 · 2021 · External reference
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
10.1038/s41467-024-47256-x · 2024 · External reference
Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing
10.1038/ni.3558 · 2016 · External reference
Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies
2024 · External reference
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
10.1136/jitc-2024-010511 · 2025 · External reference
STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells
10.1038/s41419-024-06638-1 · 2024 · External reference
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
10.1186/s40364-025-00740-y · 2025 · External reference
Clinical approaches to overcome PARP inhibitor resistance
10.1186/s12943-025-02355-1 · 2025 · External reference
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors
10.1038/s41698-024-00672-0 · 2024 · External reference
PARP inhibitor insensitivity to BRCA1/2 monoallelic mutations in microsatellite instability-high cancers
2022 · External reference
Hotspot BRCA1/2 mutations in tumors with microsatellite instability suggest passenger mutation status and may confound targeted therapy selection
2025 · External reference
Complete response to pembrolizumab in a patient with castration-resistant prostate cancer with both BRCA positivity and a high frequency of microsatellite instability: a case report
10.1159/000540419 · 2024 · External reference
Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer
2025 · External reference
